Literature DB >> 11865643

[A case of advanced hypopharyngeal carcinoma successfully treated with superselective intra-arterial infusion of docetaxel].

Takeshi Akisada1, Tamotsu Harada, Takuji Takemoto, Kazuyasu Fukuda, Norimasa Morita, Teruhito Aihara, Yasumasa Kajihara, Shigeki Imai, Masayuki Gyoten, Yoshinari Imajo, Junichi Hiratsuka.   

Abstract

Docetaxel is an excellent agent with a high antitumor effect for advanced/recurrent head and neck cancer. A 67-year-old male with advanced hypopharyngeal cancer (T3N2bM1: Stage IV) underwent two courses of superselective intra-arterial infusion of docetaxel and intravenous administration of CDDP and 5-FU. Using a coaxial technique, a microcatheter was placed in the feeding artery. Using imaging techniques docetaxel (60 mg/body and 30 mg/body) was infused into the vessels. During chemotherapy the patient received concomitant radiotherapy (50 Gy). MRI after chemoradiation showed a complete response for the primary tumor and a partial response for the neck metastasis. Grade 4 leukopenia and neutropenia and grade 3 pharyngitis/esophagitis were observed during chemoradiotherapy, but these adverse effects abated immediately and were not critical. We conclude that this superselective intra-arterial infusion of docetaxel will be useful and safe for head and neck cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11865643

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement.

Authors:  Apostolia M Tsimberidou; Katherine Letourneau; Siqing Fu; David Hong; Aung Naing; Jennifer Wheler; Cynthia Uehara; Stephen E McRae; Sijin Wen; Razelle Kurzrock
Journal:  Cancer Chemother Pharmacol       Date:  2010-10-13       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.